| Christopher L Tyler, MD | |
|
2200 Ofarrell St, San Francisco, CA 94115-3357 | |
| (415) 833-2000 | |
| Not Available |
| Full Name | Christopher L Tyler |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Critical Care Medicine |
| Location | 2200 Ofarrell St, San Francisco, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023196656 | NPI | - | NPPES |
| 00G661730 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | G66173 (California) | Primary |
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Octapharma USA is supporting a new investigator initiated clinical trial led by George Sakoulas, M.D. of Sharp Memorial Hospital in San Diego, California focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing respiratory failure who become ventilator dependent.
People who recently have been infected with HIV may not be as highly infectious as previously believed, a finding that could improve global efforts to prevent HIV transmission and save lives. In particular, the finding bolsters the strategy of treating patients with antiretroviral drugs before the onset of AIDS to prevent transmission.
Administration of antibiotics may have caused successive outbreaks of vancomycin-resistant enterococci in a Greek neonatal intensive care unit, according to a study in the October issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.
Many patients with acute myeloid leukemia (AML) share a mutation in a gene called IDH. A University of Colorado Cancer Center study published this week in the journal Leukemia & Lymphoma shows that this IDH mutation may be the first domino in a chain that leads to a more aggressive form of the disease.
Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher L Tyler, MD 1800 Harrison St Fl 7, Oakland, CA 94612-3466 Ph: (510) 625-6262 | Christopher L Tyler, MD 2200 Ofarrell St, San Francisco, CA 94115-3357 Ph: (415) 833-2000 |
News Archive
Octapharma USA is supporting a new investigator initiated clinical trial led by George Sakoulas, M.D. of Sharp Memorial Hospital in San Diego, California focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing respiratory failure who become ventilator dependent.
People who recently have been infected with HIV may not be as highly infectious as previously believed, a finding that could improve global efforts to prevent HIV transmission and save lives. In particular, the finding bolsters the strategy of treating patients with antiretroviral drugs before the onset of AIDS to prevent transmission.
Administration of antibiotics may have caused successive outbreaks of vancomycin-resistant enterococci in a Greek neonatal intensive care unit, according to a study in the October issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.
Many patients with acute myeloid leukemia (AML) share a mutation in a gene called IDH. A University of Colorado Cancer Center study published this week in the journal Leukemia & Lymphoma shows that this IDH mutation may be the first domino in a chain that leads to a more aggressive form of the disease.
Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).
› Verified 2 days ago
Dr. Pratyusha Kishore Narra, MBBS Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 3490 California St, San Francisco, CA 94118 Phone: 415-514-6200 Fax: 415-514-6410 | |
Dr. Chelsea Joy Thomsen, M.D., M.S.P.H Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 W Portal Ave, San Francisco, CA 94127 Phone: 415-291-0480 | |
Christine Soran, Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1001 Potrero Ave, Bldg 10, 3rd Floor, Ward 13, Ucsf Division Of General Internal Medicine Sfgh, San Francisco, CA 94110 Phone: 415-206-5164 Fax: 415-206-5586 | |
Stephen Norris Cohen, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 40 Ventura Ave, San Francisco, CA 94116 Phone: 415-681-2171 Fax: 415-681-2171 | |
Mauricio Jalife Bucay, M.D Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 505 Parnassus Ave, San Francisco, CA 94143 Phone: 415-750-4994 Fax: 415-750-8156 | |
Dr. Adriana A.t. Martin, M.D., PH.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 505 Parnassus Ave, San Francisco, CA 94143 Phone: 415-514-7288 | |
Dr. Alexandra Cristina Villasante Fricke, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 655 Montgomery St Ste 810, San Francisco, CA 94111 Phone: 844-847-8216 Fax: 415-520-9150 |